Novo Nordisk raises 2017 forecasts despite continued US price pressure

Published Wed, Aug 9, 2017 · 09:50 PM

Copenhagen

NOVO Nordisk, the world's leading maker of diabetes drugs, reported a better than expected profit on Wednesday driven by new diabetes and obesity drugs, though it said sale prices would remain under pressure in the United States.

The Danish drugmaker shocked markets in 2016 by cutting its long-term operating profit forecasts twice on the back of price pressures in its main US market, sending its shares down more than 40 per cent last year.

The company said its second-quarter operating profit came in at 13.4 billion crowns (S$2.88 billion), above an average estimate of 12.7 billion in a Reuters poll, and raised its forecasts for both sales and operating profit this year.

"Although the formulary negotiations in the USA reflect the tough competitive environment, we remain confident that our long-term financial growth targets are achievable," chief executive Lars Fruergaard Jorgensen said.

Novo Nordisk's shares jumped more than 6 per cent and were 5.1 per cent higher at 1015 GMT, boosted by the second-quarter earnings and higher 2017 forecasts.

The company has come under pressure in the all-important US market as the pharmacy-benefit managers who administer drug programmes for employers and health plans demand ever bigger discounts for insulin drugs. Mr Jorgensen said that looking ahead, average prices after rebates were expected to be lower than in 2017, mainly driven by longer-acting basal insulin treatments, but he declined to say how far prices were expected to fall.

Pressure from politicians is adding to the uncertainty though no specific initiatives have been taken yet. US President Donald Trump said in January that pharmaceutical companies were "getting away with murder" in what they charge the government, and promised that would change.

With its traditional diabetes treatments in the firing line, Novo Nordisk is pinning its hopes for growth on new obesity drugs. Saxenda, launched in 2015, had second-quarter sales of US$194 million, or 2 per cent of Novo's overall sales, and analysts expect it to earn more than US$1 billion a year by 2023. "The growth in Saxenda is very promising," chief financial officer Jesper Brandgaard said, adding that the product was gaining "good traction" in the US, Latin America and the Middle East.

Novo's next big hope in treating obesity is Semaglutide, a new drug in the so-called GLP-1 category which imitates an intestinal hormone that stimulates the production and absorption of insulin. Used for patients who can produce some insulin, the drug is also being tested for both types of diabetes. US and European authorities are expected to decide on approval of Semaglutide as a once-weekly treatment for diabetes by the end of the year.

Novo Nordisk raised its 2017 sales growth forecast in local currencies to one to 3 per cent from zero to 3 per cent. Operating profit in local currencies is now expected to rise by one to 5 per cent compared with a range of minus one per cent to plus 3 per cent previously. REUTERS